Discover some of the latest licensing deals executed by Wake Forest Innovations. In this report, learn about the licensing of four novel technologies: a cancer therapeutic, an internal wound therapy, a treatment of Friedrich’s ataxia and a novel model of lupus.
When medical device and therapeutic companies work on a new product, there are a few vital—and challenging—steps that take place between developing technologies and introducing them into the real-world.
Wake Forest Innovations would like to introduce the newest member of the Center for Technology Innovation & Commercialization. Rick Smith, MBA, joins the Center as a licensing director with the commercialization team. In his role, Smith will support the Center’s mission to accelerate the development and commercialization of inventions from Wake Forest Baptist Medical Center continue reading
When Wake Forest Baptist Medical Center neurosurgeon Charles Branch Jr., MD, found a better way to break up blood clots during traumatic brain injury surgery, he turned to Wake Forest Innovations for help. Over the past year, the Medical Device Accelerator program has transformed his invention into a working prototype of stainless steel, springs and continue reading
Chondrial Therapeutics, an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, announced this week that it has secured up to $22.6 million in Series A financing led by Deerfield Management, a health care investment firm located in New York, New York. The financing includes an investment from the Catalyst Fund, a $15 continue reading
The journey from scattered notes on a cocktail napkin to a licensed medical technology can be daunting—a quest packed with high attrition rates and the risks that come from the dynamic nature of science and the marketplace.
Discover some of the latest licensing deals executed by Wake Forest Innovations. In this report, learn about the licensing of novel technologies: a cancer therapeutic, a graft for heart valve replacement and a delivery method for oral medications.
Pappas Capital and Wake Forest Innovations today announced the first technologies to receive initial investment from the Catalyst Fund, the $15 million technology development program established by Wake Forest Baptist Medical Center in October 2015.
Local and national critical care experts will gather at the Bowman Gray Center for Medical Education on January 9 for the Sepsis Summit, presented by the Critical Illness, Injury and Recovery Research Center (CIIRRC) of the Wake Forest School of Medicine.